LV-320 is a potent and non-competitive ATG4B inhibitor (IC50 = 24.5 µM; Kd = 16 µM) that suppresses ATG4B enzymatic activity, blocks autophagic flux, and exhibits in vivo stability, low toxicity, and biological activity; it increases levels of LC3B-II and p62 in multiple cancer cell lines (SKBR3, MCF7, JIMT1, and MDA-MB-231) in a dose-dependent manner and enhances GFP-LC3 puncta accumulation and LC3B-II protein levels in GFP-LC3 transgenic mice without significant toxicity.